{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "2b841d7d58a7258365fdfedc57fbe8a7",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/BMYCYTK Thoughts Heading Into ESC25BMYCYTK Thoughts Heading Into ESC25_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:17:08.000858",
      "extracted_at": "2025-10-26T12:17:08.000875"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 12,
        "successful_pages": 12,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 13,
          "reduction_ratio": 0.19861008278925762
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "3c60e3e77076ad2f",
      "text": "Equity ResearchAugust 28,2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "0084de89c5ba5f30",
      "text": "We're tracking a few impt ESC presentations for CYTK: 1) BMY's full nHCM data where CYTK could have a better shot on replicating Ph.2 efficacy signals & getting more pts onto higher doses, 2) MAPLE data for afi vs metoprolol to promote 1L use esp in pts contraindicated for beta blockers (~25% of pts), 3)updated FOREST & integrated safety analyses incl AF incidence.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "619e650e6ab1cc79",
      "text": "**Bottom line:** While we wait for CYTK's upcoming PDUFA for aficament in oHCM (Dec 26th), we wanted to flag some of the key presentations at ESC well be watching for CYTK:",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b7c54b3ab1672070",
      "text": "**#1. We'll get BMY's full ODYSSEY nHCM data - post the topline miss (HERE), we think there's** **oppty for CYTK's ACACIA (exp 1H'26) to differentiate in nHCM provided we have visibility on some** **key Q's:**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b8ff6d982f9d60c0",
      "text": "· **BMY mgmt prev indicated to us that they believe mava showed benefit, although not** **stat sig vs pbo - we suspect p-values might have been borderline & titration issues or** **pbo variability cut into powering. By our illustrative power analysis, afi's KCCQ benefit in** **nHCM pts in REDWOOD/FOREST (+10~14pts) suggests they can hit stat sig vs hypothetical** **pbo response of ~+4-5 (from MAVERICK) assuming efficacy signals are replicated. CYTK** indicated they're aiming to reproduce those effects by keeping many consistencies w/ their prev nHCM cohorts incl. same titration schedule, confirming nHCM diagnosis by manually reviewing echo's, and overlapping trial centers - we est. ~95% of REDWOOD centers carried **fwd to ACACIA vs ~70-75% for MAVERICK/ODYSSEY.**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "91ac723a5bd94377",
      "text": "· **If fewer pts than expected reached 15mg in ODYSSEY & many ended up at 1mg, this might** **have diluted tx benefit in ITT pop. In mava's nHCM Ph.2, ~11-21% of pts underwent dose d/** c due to LVEF issues & interestingly, BMY's protocol allowed EF-based down-titration to 1mg (likely sub-tx)- we est. ~27-34% of pts got onto 15mg in ODYSSEY by our illustrative dosing **math (caveats apply). In comparison, in CYTK's REDWOOD and FOREST nHCM cohorts, ~86%** **of pts (35/41) reached the top 15mg dose & ~7% had asymptomatic EF&lt;50 issues using a** **similar dosing protocol as ACACIA, with additional optionality for a 20mg dose which ~65%** **of nHCM pts in FOREST pts titrated up to.**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "63d7b8b429caa887",
      "text": "ACACIA updated endpoint trial powering illustrative analysis *JEF Est* (assuming 90% power, alpha 0.025)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "65d576708a360d53",
      "text": "EndpointAssumed pbo fromMAVERICK (w&16)tx diff for powering(CYTK comments)Afi arm threshold absresponse for stat sig atwk36REDWOODnHCM Cohort 4abs responseFOREST nHCMcohort absresponseKCCQ-CSS CFB+4.34 pts+5 pts+9.34pts+10pts at wk10+13.8pts at wk36pVO2 CFB+0.01mL/kg/min+1.0mL/kg/min+1.58mL/kg/minNRNR",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "784b4946eb615b86",
      "text": "**#2. On MAPLE (afi H2H vs beta blocker SoC), we believe is an impt trial and could promote 1L use,**esp in pts who are contraindicated for beta blocker use (~25% of pts). Last year at ESC (HERE),we saw #FOREST data where 42% of pts who attempted SoC withdrawal achieved Afi monotx w/ **o compEmising efficacy or safety. Mgmt prev indicated pVO2 benefit there might look similar to**SEQUOIA's ~1.74mL/kg/min & noted that label expansion would likely be in '26.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3dac78e83af8e0e1",
      "text": "**note** **contd on pg3**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6fa27de2abdcfede",
      "text": "2024A2025E2026E2027ECons. Rev.12.0177.5439.5912.3Rev. (MM)18.59.0356.0539.0EV/RevNMNM12.3x8.1xP/RevNMNM12.7x8.4x",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a2e31b3bbc545939",
      "text": "ESTIMATE CHANGERATINGBUYPRICE&#36;37.83*PRICE TARGET | % TO PT&#36;70.00|+85%52W HIGH-LOW&#36;59.39-&#36;29.31FLOAT (%)|ADV MM (USD)96.6%|54.24MARKET CAP&#36;4.5BTICKERCYTK",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62c3b166963fa39d",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "55cc9ed6a126bf87",
      "text": "FY (Dec)CHANGE TO JEFeJEF vs CONS2025202620252026REVNA-10%-95%-19%EPS-355%-4%-2%-28%2025 ($)Q1AQ2AQ3Q4 FYEPS(1.36)(1.12)(1.52)(1.54) (5.55)PREV(1.22)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "edbc8f35647d848d",
      "text": "**Akash Tewari * | Equity Analyst**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "32750f95d2aaf9b5",
      "text": "**Amy Li, PharmD * | Equity Analyst**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "38fbff1391c82252",
      "text": "**Phoebe Tan * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7ae2775bd2e0a5c8",
      "text": "**Anastasia Parafestas * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a51f516f0836a50e",
      "text": "**Katherine Wang * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9415c66c2b728e68",
      "text": "**Manoj Eradath, MBBS, Ph.D. * | Equity**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ccc8ffaabf986b41",
      "text": "**Zaki Molvi, PhD * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1616921a5bc81bfb",
      "text": "**Albert Zhang, CPA * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7ae97bca167b69b8",
      "text": "1) At \\(\\sim\\) 88Bn, CYTK trades at a significant discount to what BMY paid for MYOK (\\$13Bn), which has a drug with a similar mechanism of action. 2) Our analysis suggests CYTK's drug, having a wider therapeutic window, could treat more severe pts than the MYOK asset; in fact, we think there are \\(\\sim 22\\%\\) of oHCM pts who wouldn't be able to be effectively treated with the BMY/MYOK drug, which CYTK could address. This could represent a \\(\\) 700m\\(opportunity over time. 3) CK - 274 gets HCM pts to their therapeutic dose significantly more quickly than MYOK (\\~1.5mo vs \\~4mo) and can be titrated without using PD measures - which should allow CYTK to have a more attractive commercial profile and be a viable alternative vs HCM surgery.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "20fd438043f8c237",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a96471a47b06ac76",
      "text": "Base Case, \\(\\) 70\\(,\\) +85\\%\\$",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d4a53782422fe102",
      "text": "Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%;",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0da73cac64eab6bd",
      "text": "Omecamitv Mecaribl: POS in HFrEF: 0%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9d07c8e8df129adb",
      "text": "PT of \\(\\) 70\\$ is DCF- based",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "affbdc6d50e4ba74",
      "text": "Upside Scenario, \\(\\) 142\\(,\\) +275\\%\\$",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8af8f88cb78dff25",
      "text": "Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%;",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c782578392e76be0",
      "text": "Omecamitv Mecaribl: POS in HFrEF: 20%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fbfb4eb89a91f12f",
      "text": "Upside PT of \\(\\) 142\\$ is DCF- based",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "51033b57f86c706b",
      "text": "Downside Scenario, \\(\\) 30\\(,\\) - 21\\%\\$",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7102c56366e02bab",
      "text": "Aficamten (CK- 274): POS in mild/mod oHCM: 75%, Peak Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%;",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a5ca4f220d6e6987",
      "text": "Omecamitv Mecaribl: POS in HFrEF: 0%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fab4df95a60ef4c0",
      "text": "Downside PT of \\(\\) 30\\$ is DCF- based",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "eb77fe67e1d8c56f",
      "text": "1. Product Quality & Safety: With 3 late-stage potential medicines in development and more on horizon, CYTK is pursuing the vision to be the leading muscle biology biopharmaceutical company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to novel medicines arising from its research.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5c575cfa3fff10e4",
      "text": "1. Improvements the lives of people living with devastating cardiovascular and neuromuscular diseases",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a95aaec9b4ef4e41",
      "text": "Do you have plans on collaborating with large-cap pharmaceutical companies to make your product more accessible to a larger patient's base? What types of partnership are you thinking right now?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cbcfaecb42012508",
      "text": "2. What are the other major markets that you will be focusing on outside the U.S.?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b2852ee024db8cd9",
      "text": "ESG Sector Deep Dive: Healthcare",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e33d60ba607eab96",
      "text": "**#3. We'll see additional Afi analyses for FOREST as well as integrated safety analyses that includes data on atrial fibrillation (AF) incidence.** Last year at ESC, we saw an Integrated safety anal ysis (n=283 pts) showing low LVEFACACIA-HCM (Aficamten, CYTK)ODYSSEY-HCM (Mavacamten, BMY)Echo governance &titrationSite-read echoes; start 5 mg QD, uptitrate to 10/15/20 mg at Wks 2/4/6. Rules: uptitrate ifEF ≥60%; hold 50-&lt;60; downtitrate if &lt;50, temp DC/if &lt;40.Core-lab-read echoes; start 5 mg QD; down-titrate Wks 5 & 9, up-titrate Wks 12/24/36;range 1-15 mg. Interrupt if EF &lt;50%, permanent DC/if &lt;30.AF criteriaAF allowed if rate-controlled. Higher NP thresholds if in AF (≥900 pg/mL, Black ≥675Non-permanent AF excluded; permanent AF allowed if anticoagulated and rate-controlledBiomarker / diastolicenrichmentNT-proBNP ≥300 (≥900 if AF), Black: ≥225 (≥675 if AF). No mandatory diastolic-ths-Tnenrichment.NT-proBNP ≥200 (or BNP ≥70; higher if AF) plus ≥1 required criteria criteria (hs-troponin&gt;99% ULN, or E/e' &gt;14, or LAVI &gt;34 mL/m²).CPET / oxygenationCPET required: RER ≥1.0 and pVO&gt;90% predicted. Exclusion if SpO&gt;90% at rest.CPET required: RER ≥1.0 and SpO&gt;90% at rest (core-lab read).Inclusion: LVOT &wall thicknessnHCM: LVOT-G &lt;30 mmHg rest &lt;50 provocation; EF ≥60%; wall thickness ≥15 mm or≥13 mm + FHx/genetics. KCCQ-CSS 30-85.Similar LVOT & EF cut-offs. Wall thickness ≥15 mm (≥13 mm + FHx) KCCQ-CSS ≤85. Allecho criteria core-lab verifiedExclusions (key diffs)Excludes resistant HTN, O&gt; sat &lt;90%, recent syncope/VT with exertion, inability to exercise,prior mava/aficamten, SRT &lt;6 mo, transplant/LVAD planned.Excludes non-permanent AF, severe valvular disease needing surgery, LV aneurysm ≥2 cm,strong CYP2C19 inhibitors. Mid-cavity/apical HCM and post-SRT allowedPrimary endpoints &timingKCCQ-CSS @ wk36 (now dual co-primary: KCCQ-CSS + pVO&gt; both at wk36).Co-primary: KCCQ-23 CSS + pVO&gt; @ wk48; positive if either sig.Visit cadence /durationPart 1 runs to wk36, Part 2 runs to wk72, echoes dense early (D1, wks 2/4/6/8/12/24/36..).CPET BL & wk36; 4-wk washout, then OLE.Part A: DB out to wk48; Part B: pbo-mava crossover wk48-96; Part C: OL to wk156; 120dfollow-up. CPET at BL & wk48.IntracavitaryobstructionNot explicitly described in IE criteria.Patients with intraventricular (mid-cavity) obstruction eligible if no LVOT obstruction present.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a300cde470c7b639",
      "text": "Additionally, CYTK mgmt mentioned that they kept many trial centers similar between ACACIA and prev. afi trials - looking at the CT gov trial listings,we counted that ~95% of REDWOOD Ph.2 trial centers were rolled forward into ACACIA then expanded broadly (135 sites total with ~50/50 US/ex-US).BMY, in comparison, had slightly lower continuity at ~70-75% of centers from MAVERICK carried forward to ODYSSEY (224 sites total, ~120 ex-US).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "37b48397de40cd8d",
      "text": "Trial center comparison for BMY vs CYTK (based on CT.gov listed sites)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e66b8c80a7eb3012",
      "text": "Phr 2 Sites(Total)Ph.2 USPh.2 ex-USPhase 3 TrialPh.3 Sites(Total)Ph.3 USPh.3 ex-USSitesRolledForwardForward% RolledForwardfrom Ph.2BMYMAVERICK (nHCM,Ph.2)32320ODYSSEY(nHCM, Ph.3)224~100+~120+~22-24(US only)~70-75%(US only)CYTKREDWOOD (o/nHCM,Ph.2)22193ACACIA(nHCM, Ph.3)135~70-75~60-65~21~95% (US+ ex-US)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "41bc972340a1057f",
      "text": "Source: JEF Analysis, CT.gov",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7bb20ad9fc7efc61",
      "text": "In the full ODYSSEY data, we'll be paying attention to % of pts achieving 1Smg dose - our est. suggests this could be up to ~27-34% of pts:",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c97e815c03db6906",
      "text": "Going into ESC, one thing we'll be paying attention to is how many pts got onto the max dose for Mavacamten. In BMY's mava dosing paper (Merali et al), they showed a PKPD simulation integrating echo-guided (vLVOT and LVEF) titration to estimate dose distribution in oHCM. At week 48 (ODYSSEY's endpoint), ~19% of pts were estimated to be at the max 15mg dose.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5963c8cdf98972b9",
      "text": "Since ODYSSEY's nHCM pop doesn't have LVOT criteria to cap the dose, we wanted to see how much higher the mava dose could get if gated on EF criteria alone using the following illustrative adjustments:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b2f5281bdf5fec3a",
      "text": "We started from the \\(\\sim 19\\%\\) modeled by BMY for oHCM in merali et al, then we estimated a combined oHCM \"pass rate\" for being eligible for uptitration, e.g., probability of both LVEF \\(\\geq 55\\%\\) and vLVOTg \\(\\geq 30\\mathrm{mmHg}\\) . We estimated this to be \\(90\\% \\times 60\\% = \\sim 54\\%\\) . \\(90\\%\\) corresponds to probability of LVEF \\(\\geq 55\\%\\) and is on the upper end of expectations, and \\(\\sim 60\\%\\) is probability of LVOT \\(\\geq 30\\) comes from Mava's EXPLORER-HCM where \\(57\\%\\) of pts achieved post exercise LVOT \\(Description% of ptsBase 15 mg % from ER Model19%% with LVEF ≥55% (eligible based on EF)90%% with both LVEF ≥55% and LVOT ≥30 mmHg54%Relative increase in eligible patients w/o LVOT gate1.67Theoretical max 15 mg % in ODYSSEY32%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a2555d9061e90139",
      "text": "REDWOOD cohort 4  Figure 3: 35 patients (8%) achieved daily aftertome dose of pts. 6 patients (15%) achieved 10 mg. 1 patient on 10 mg. 1 patient on 10 mg. 1 patient on 10 mg",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9625e480fa1b2569",
      "text": "Source: JEF Analysis, Company Presentations",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6e68d13a8464af8a",
      "text": "Putting it together, we estimate the theoretical upper end of ODYSSEY pts getting on 15mg could be \\(\\sim 27 - 34\\%\\) . In comparison, CYTK's nHCM cohort 4 (n=41) in Ph.2 REDWOOD saw \\(85\\%\\) of pts (35/41) reaching the max 15mg dose by wk10 + in FOREST OLE, \\(\\sim 65\\%\\) of nHCM pts were able to get onto 20mg after titration. Note that Mava's Ph.2 MAVERICK in nHCM randomized pts to exposure targets of \\(\\sim 200\\mathrm{mg / mL}\\) (group 1) or \\(\\sim 500\\mathrm{mg / mL}\\) (group 2) rather than dosing a single cohort up.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5cb7cfbed8fe34a6",
      "text": "We'll also flag that BMY hasn't disclosed the uptitration eligibility criteria for ODYSSEY yet - we're assuming it would be similar to the Camzyos label dosing eligibility but w/o LVOT criteria, i.e., LVEF \\(\\geq 55\\%\\) at wk12+Q12W, BMY didn't confirm this to us yet and indicated they'll provide details when they present the full data.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6a8b88fcada827d7",
      "text": "We'll also be looking at possible dose response on primaries like KCCQ & pVO2 given the benefit shown in CYTK's REDWOOD C4 & FOREST nHCM cohorts",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d636b32e0ee00934",
      "text": "BMY's design paper mentioned testing the dual primary endpoints (pVO2, KCCQ) in ITT w/ a graphical testing strategy, controlling the overall type I error rate at 0.05 (2- sided). We'd be interested in seeing how their hypothesis weighting and hierarchical assignments were given between the dual primary endpoints and whether those assumptions contributed to the trial missing the endpoints. Post regulator feedback, CYTK is using a dual primary endpoint (KCCQ & pVO2) w/ either/or criteria similar to ODYSSEY. By our illustrative powering analysis, af's KCCQ benefit in nHCM pts in REDWOOD & FOREST (+10- 14pts at wks 10- 36) suggests they can hit stat sig vs hypothetical pbo response of \\(\\sim +4 - 5\\) (from MAVERICK) assuming these efficacy signals are replicated.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "816129279500344f",
      "text": "Source: JEF Analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "547af069610a2d2d",
      "text": "ACCIA updated endpoint trial powering illustrative analysis 'JEF Est' (assuming \\(90\\%\\) power, alpha 0.025)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cd21472638635c7b",
      "text": "EndpointAssumed pbo from MAVERICK (wk18)tx diff for powering (CYTK comments)All arm threshold abs response for stat sig at wk36REDWOOD nHCM Cohort 4 abs responseFOREST nHCM cohort abs responseKCCQ-CSS CFB+4.34 pts+5 pts+9.34pts+10pts at wk10+13.8pts at wk36pVO2 CFB+0.58mL/kg/min+1.0mL/kg/min+1.58mL/kg/minNRNR",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8bad187331d63278",
      "text": "On pVO2, we have more limited data on the benefit there in nHCM - we didn't see this reported for CYTK's REDWOOD cohort 4 or FOREST, and in BMY's MAVERICK the benefit observed wasn't dose- ordered & was lower vs (+0.36 at \\(\\sim 200mg / mL\\) , +0.12 at \\(\\sim 500mg / mL\\) vs +0.58 pbo). That said, we'll note CYTK only needs to hit stat sig on one component of the dual endpoint (KCCQ or pVO2), for the trial to read positive.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "35627d39f8e46a35",
      "text": "Earlier this year, we got the MAPLE topline showing stat sig pVO2 benefit for aficamten vs metoprolol & favorable safety at 24wks. The PR didn't give numerical details, but we'll note MAPLE was \\(>90\\%\\) powered to detect a \\(+2mL / kg / min\\) pVO2 delta on afi vs metoprolol. There isn't a clear read on pVO2 benefit on metoprolol but we've seen limited data suggesting it might be on the lower end - e.g., TEMPO crossover trial \\((n = 29)\\) showed metoprolol lowered LVOT- G and improved NYHA/KCCQ but pVO2 wasn't sig. diff vs pbo.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c772433e7ac3ead6",
      "text": "Since the topline PR didn't disclose details on secondaries (mgmt indicated some details had to be left out as part of the conference embargo), we'll be looking at secondaries like KCCQ benefit in the full data in addition to pVO2. We'll note that although MAPLE hit stat sig on pVO2, we've seen a pretty modest correlation between pVO2 and KCCQ ( \\(r = 0.31 \\sim 0.36\\) reported in Nassif et al).",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "685798a9a06ad4f7",
      "text": "Source: Company Publications",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d17e875174e23397",
      "text": "Mgmt believes MAPLE could help drive adoption in community cardiologists who believe that beta blockers (BB) are good enough for pts - \\(90\\%\\) of symptomatic HCM pts are being treated with BB, calcium channel blocker, or both and majority are being treated in community setting. MAPLE data will also give a read on tolerability comparison (so far beta blockers have generally been associated w/ more AE's vs Afi). In terms of development of AF, MAPLE might not be able to show the difference in risk here since the study is excluding pts w/ hx of AF.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "52292790dd06b77d",
      "text": "MAPLE also includes a patient experience substudy that includes qualitative interviews, which could help show some overlooked impact of beta blockers to patient QoL (pts often report feeling cold, tired, lethargic) - this could shed light on AE's of fatigue, impotence, depression as well as symptomatic bradycardia or hypotension which could prompt pts in either arm to down- titrate.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9af0c845413503e2",
      "text": "== Income Statement ==",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a8cbbec0e47fe266",
      "text": "(in millions, except per share amounts)2025202620272028202920302031203220332034203520362037203820392040JefferiesTotal RevenueDiluted EPS$ 9($ 5.55)$ 356($ 3.35)$ 539($ 2.13)$ 842($ 1.17)$ 1,260$ 0.97$ 1,741$ 2.79$ 2,145$ 4.69$ 2,331$ 5.38$ 2,461$ 5.83$ 2,591$ 6.38$ 2,693$ 6.77$ 2,765$ 7.02$ 2,838$ 7.26$ 2,912$ 7.53$ 2,986$ 7.78$ 2,671$ 7.15",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "41bcd77c849abe95",
      "text": "GAAP PNLProduct sales52015358381,2561,7372,1412,3272,4572,5872,6892,7612,8342,9072,9812,667R&D revenue44444444444444444License revenue-------Milestone/royalty Revenues-150-----Total revenues93565398421,2601,7412,1452,3312,4612,5912,6932,7652,8382,9122,9862,671Cost of sales15899267232321331361383405421432443454465418Gross profit82984405741,0281,4201,8141,9702,0782,1872,2722,3332,3952,4582,5202,253R&D442455469471479487493501509518522528536544552481SG&A257281308328347366375385394396401406412413418347Other-------Operating income(690)(438)(337)(225)2025679461,0841,1751,2721,3481,3991,4471,5001,5501,425Interest expense(45)(43)(30)(20)(20)(20)(20)(200)(20)(7)(7)(7)(7)(6)(7)(7)Other(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)(40)Interest and other income51515151515151515151515151Pre-tax income(724)(470)(357)(235)1935579361,0751,1651,2761,3521,4021,4511,5031,5541,429Income taxes--(37)(47)39111187215233255270280290301311286Net income(724)(470)(319)(188)1554467498609321,0201,0821,1221,1611,2031,2431,143Share count, basic130140150160160160160160160160160160160160160Share count, diluted130140150160160160160160160160160160160160160GAAP EPS - basic$ (5.55)$ (3.35)$ (2.13)$ (1.17)$ 0.97$ 2.79$ 4.69$ 5.38$ 5.83$ 6.38$ 6.77$ 7.02$ 7.26$ 7.53$ 7.78$ 7.15GAAP EPS - diluted$ (5.55)$ (3.35)$ (2.13)$ (1.17)$ 0.97$ 2.79$ 4.69$ 5.38$ 5.83$ 6.38$ 6.77$ 7.02$ 7.26$ 7.53$ 7.78$ 7.15",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d82bdd414df913ba",
      "text": "Source: JEF Analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cfcbe1b7bd223524",
      "text": "Cytokinetics, Inc. focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4914a2922c1f8b5e",
      "text": "Price target is DCF- based. Risks include commercial, clinical, and regulatory issues, as well as competitive risks.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "368a814a57c7520f",
      "text": "Valuation: Our DCF- based PT is supported by PE and PEG- relative valuations. Risks: R&D, LOEs, pricing, competition, legal/regulatory, M&A.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "62ed0b2fb1b1135e",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "367e5691ef308606",
      "text": "August 28, 2025 9:25 A.M. August 28, 2025 9:25 A.M.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "96ff8ca13ac112b4",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Cytokinetics Inc within the next three months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5aa71afd513b1a93",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Cytokinetics Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6021fb6b994a189f",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Cytokinetics Inc or one of its affiliates.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5f54da81486ddcd6",
      "text": "Within the past twelve months, Cytokinetics Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c9a23774f57d1ed5",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Cytokinetics Inc or one of its affiliates within the past twelve months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3eab2067ab0058be",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(\\) 10\\(is 20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below\\) \\ \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(\\) 10\\(, the expected total return (price appreciation plus yield) is minus\\) 20\\% \\(or less within a 12- month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fe0c4473c696abf1",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "27da0fc298981a36",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2e1cf07b96767c5d",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "067c4f914711c12a",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3cb93c741f600781",
      "text": "Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4d3fd96f0d036d66",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d1d3df7d9837a32a",
      "text": "- Bristol-Myers Squibb Co (BMY: \\(\\) 47.63\\(, BUY) \n- Cytokinetics Inc (CYTK:\\) \\ \\(37.83\\) , BUY)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5c997227933b7f2e",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "3be1890b578a2865",
      "text": "I: Initiating Coverage",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "86a87eb551a93ff7",
      "text": "Distribution of Ratings",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4c3797b6d606bb14",
      "text": "Distribution of RatingsIB Serv./Past12 Mos.JIL Mkt Serv./Past12 Mos.CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e7077b9c0a0ea61a",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c87a0b601fd7bcb9",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "816907313d2e6a5e",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b220854711acad4c",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9302047f2ab61e2f",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "70f1aa92cac05499",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5cea4db2141e1e9e",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "ec9954515353cc4c",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "e4f69410aa191c50",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "177462aa83828ffe",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9f92c959ee9ecbe8",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9c53b48149a4ecb4",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0df40ce78b62e0ac",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "38355c02497c0a12",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fea02373cf42be18",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b06140b87f97b112",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "87b9adaccc528924",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e5415b2c287d41d8",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 11,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "4a33cb349f05027c",
      "name": "Akash Tewari",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8e94099e7d77d72c",
      "name": "Albert Zhang",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b876846393e041b3",
      "name": "Amy Li",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "29ab11ba60a952b1",
      "name": "Anastasia Parafestas",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5ebd7a32d0e24d57",
      "name": "At ESC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7d006fa110a780d5",
      "name": "Biotechnology\n\nCytokinetics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "baf427d7e8c704f4",
      "name": "Co\n\nValuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6f986239a1ef9bc4",
      "name": "Company Presentations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a0955429147ae9b9",
      "name": "Company Publications",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0c759b57d9ad2ce6",
      "name": "Company Specific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1667fe8e404dda52",
      "name": "Comparing CYTK",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "242108e6f8c99feb",
      "name": "Cytokinetics\n\nCytokinetics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "897a39bcc0d6a507",
      "name": "Cytokinetics\n\nPrice",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c341d437fa6c4157",
      "name": "Cytokinetics Inc",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "8db5e96490f60501",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 20,
              "max": 160
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2023-10",
                "y": 30
              },
              {
                "x": "2023-11",
                "y": 35
              },
              {
                "x": "2023-12",
                "y": 32
              },
              {
                "x": "2024-01",
                "y": 40
              },
              {
                "x": "2024-02",
                "y": 85
              },
              {
                "x": "2024-03",
                "y": 105
              },
              {
                "x": "2024-04",
                "y": 80
              },
              {
                "x": "2024-05",
                "y": 70
              },
              {
                "x": "2024-06",
                "y": 55
              },
              {
                "x": "2024-07",
                "y": 60
              },
              {
                "x": "2024-08",
                "y": 50
              },
              {
                "x": "2024-09",
                "y": 58
              },
              {
                "x": "2024-10",
                "y": 52
              },
              {
                "x": "2024-11",
                "y": 45
              },
              {
                "x": "2024-12",
                "y": 40
              },
              {
                "x": "2025-01",
                "y": 35
              },
              {
                "x": "2025-02",
                "y": 30
              },
              {
                "x": "2025-03",
                "y": 38
              },
              {
                "x": "2025-04",
                "y": 42
              },
              {
                "x": "2025-05",
                "y": 50
              },
              {
                "x": "2025-06",
                "y": 55
              },
              {
                "x": "2025-07",
                "y": 60
              },
              {
                "x": "2025-08",
                "y": 58
              },
              {
                "x": "2025-09",
                "y": 55
              },
              {
                "x": "2025-10",
                "y": 40
              }
            ]
          },
          {
            "name": "Upside Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025-10",
                "y": 40
              },
              {
                "x": "+12 mo.",
                "y": 142
              }
            ]
          },
          {
            "name": "Midpoint Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025-10",
                "y": 40
              },
              {
                "x": "+12 mo.",
                "y": 70
              }
            ]
          },
          {
            "name": "Downside Forecast",
            "unit": null,
            "values": [
              {
                "x": "2025-10",
                "y": 40
              },
              {
                "x": "+12 mo.",
                "y": 30
              }
            ]
          }
        ],
        "figure_id": "0dbd533383ea0833",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "b8034716e124961b",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": "nHCM KCCQ-CSS mean CFB",
        "page": 4,
        "axes": {
          "x": {
            "type": "linear",
            "labels": "weeks"
          },
          "y": {
            "unit": "KCCQ-CSS",
            "range": {
              "min": 0,
              "max": 16
            }
          }
        },
        "series": [
          {
            "name": "Afi REDWOOD C4 (N=41)",
            "unit": "KCCQ-CSS",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 10,
                "y": 10.5
              }
            ]
          },
          {
            "name": "Afi FOREST nHCM (N=34)",
            "unit": "KCCQ-CSS",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 36,
                "y": 13.8
              }
            ]
          },
          {
            "name": "Mava MAVERICK ~200ng/mL (N=19)",
            "unit": "KCCQ-CSS",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 16,
                "y": 0.1
              }
            ]
          },
          {
            "name": "Mava MAVERICK ~500ng/mL (N=21)",
            "unit": "KCCQ-CSS",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 16,
                "y": 5.8
              }
            ]
          },
          {
            "name": "Pbo MAVERICK (N=19)",
            "unit": "KCCQ-CSS",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 16,
                "y": 4.3
              }
            ]
          }
        ],
        "figure_id": "01ca3c64c51abeb0",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "table",
        "title": "Cross-Sectional Construct Validity of KCCQ in Patients With oHCM at Baseline",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "NYHA Functional Class (n = 196)",
              "KCCQ Shortness of Breath (n = 195)",
              "KCCQ Tiredness (n = 195)",
              "KCCQ CV Symptoms (n = 195)",
              "EQ-5D VAS (n = 196)",
              "pVO2 (n = 196)",
              "Exercise Duration (n = 196)",
              "WPAI (n = 194)"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Overall summary",
            "unit": null,
            "values": [
              {
                "value": -0.43,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.68,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.65,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.57,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.38,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.35,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.35,
                "p_value": "< 0.0001"
              },
              null
            ]
          },
          {
            "name": "Clinical summary",
            "unit": null,
            "values": [
              {
                "value": -0.45,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.7,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.65,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.53,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.38,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.35,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.39,
                "p_value": "< 0.0001"
              },
              null
            ]
          },
          {
            "name": "Total symptoms",
            "unit": null,
            "values": [
              {
                "value": -0.44,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.69,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.68,
                "p_value": "< 0.0001"
              },
              {
                "value": -0.53,
                "p_value": "< 0.0001"
              },
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Physical limitation",
            "unit": null,
            "values": [
              {
                "value": -0.4,
                "p_value": "< 0.0001"
              },
              null,
              null,
              null,
              null,
              {
                "value": 0.38,
                "p_value": "< 0.0001"
              },
              {
                "value": 0.38,
                "p_value": "< 0.0001"
              },
              null
            ]
          },
          {
            "name": "Quality of life",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              {
                "value": 0.57,
                "p_value": "< 0.0001"
              },
              null,
              null,
              null
            ]
          },
          {
            "name": "Social limitation",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              {
                "value": -0.56,
                "p_value": "< 0.0001"
              }
            ]
          }
        ],
        "figure_id": "ec399a049d430b86",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Cytokinetics Inc (CYTK) as of 08-27-2025",
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "USD",
            "range": {
              "min": 20,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "USD",
            "values": [
              55,
              45,
              50,
              40,
              30,
              110,
              70,
              55,
              50,
              40,
              30,
              40
            ]
          },
          {
            "name": "BUY $93.00",
            "unit": "USD",
            "date": "12/27/2023"
          },
          {
            "name": "BUY $95.00",
            "unit": "USD",
            "date": "01/25/2024"
          },
          {
            "name": "BUY $85.00",
            "unit": "USD",
            "date": "05/23/2024"
          },
          {
            "name": "BUY $92.00",
            "unit": "USD",
            "date": "08/22/2024"
          },
          {
            "name": "BUY $70.00",
            "unit": "USD",
            "date": "02/07/2025"
          }
        ],
        "figure_id": "6c532bbb64c1c4e1",
        "provenance": {
          "page": 9
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "9ac024d4f2c622df",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") MAPLE data for afi vs metoprolol to promote 1L use esp in pts contraindicated for beta blockers (~25% of pts), 3)updated FOREST & integrated safety analyses incl AF incidence. **Bottom line:** While",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c4046f8136bd293d",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e, confirming nHCM diagnosis by manually reviewing echo's, and overlapping trial centers - we est. ~95% of REDWOOD centers carried **fwd to ACACIA vs ~70-75% for MAVERICK/ODYSSEY.** · **If fewer pts t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "54c084b4db7efbfb",
        "value": -0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ho's, and overlapping trial centers - we est. ~95% of REDWOOD centers carried **fwd to ACACIA vs ~70-75% for MAVERICK/ODYSSEY.** · **If fewer pts than expected reached 15mg in ODYSSEY & many ended up ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ae1451732e4082f9",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "& many ended up at 1mg, this might** **have diluted tx benefit in ITT pop. In mava's nHCM Ph.2, ~11-21% of pts underwent dose d/** c due to LVEF issues & interestingly, BMY's protocol allowed EF-based",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "280d5f552a82d5c3",
        "value": -0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "& interestingly, BMY's protocol allowed EF-based down-titration to 1mg (likely sub-tx)- we est. ~27-34% of pts got onto 15mg in ODYSSEY by our illustrative dosing **math (caveats apply). In comparison",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3d743d6f47c97659",
        "value": 0.86,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ustrative dosing **math (caveats apply). In comparison, in CYTK's REDWOOD and FOREST nHCM cohorts, ~86%** **of pts (35/41) reached the top 15mg dose & ~7% had asymptomatic EF&lt;50 issues using a** **",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "51e10bea1341e9be",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "on, in CYTK's REDWOOD and FOREST nHCM cohorts, ~86%** **of pts (35/41) reached the top 15mg dose & ~7% had asymptomatic EF&lt;50 issues using a** **similar dosing protocol as ACACIA, with additional o",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "559314994a11d8ec",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s using a** **similar dosing protocol as ACACIA, with additional optionality for a 20mg dose which ~65%** **of nHCM pts in FOREST pts titrated up to.** ACACIA updated endpoint trial powering illustrat",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c56480ec2f6cf943",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "titrated up to.** ACACIA updated endpoint trial powering illustrative analysis *JEF Est* (assuming 90% power, alpha 0.025) <table><tr><td>Endpoint</td><td>Assumed pbo from<br>MAVERICK (w&16)</td><td>t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ff8ead8dcee89cc8",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "an impt trial and could promote 1L use,**esp in pts who are contraindicated for beta blocker use (~25% of pts). Last year at ESC (HERE),we saw #FOREST data where 42% of pts who attempted SoC withdrawa",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7804ed4a27587204",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ntraindicated for beta blocker use (~25% of pts). Last year at ESC (HERE),we saw #FOREST data where 42% of pts who attempted SoC withdrawal achieved Afi monotx w/ **o compEmising efficacy or safety. M",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "00749638e9ca9650",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>PRICE</td><td>&#36;37.83*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>&#36;70.00|+85%</td></tr><tr><td>52W HIGH-LOW</td><td>&#36;59.39-&#36;29.31</td></tr><tr><td>FLOAT (%)|ADV MM (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3f67ee843082b918",
        "value": 0.966,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>52W HIGH-LOW</td><td>&#36;59.39-&#36;29.31</td></tr><tr><td>FLOAT (%)|ADV MM (USD)</td><td>96.6%|54.24</td></tr><tr><td>MARKET CAP</td><td>&#36;4.5B</td></tr><tr><td>TICKER</td><td>CYTK</td><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "81e95361e650661e",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td></td><td>2025</td><td>2026</td><td>2025</td><td>2026</td></tr><tr><td>REV</td><td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-2",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "baaa4d75b288b5aa",
        "value": -0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2025</td><td>2026</td><td>2025</td><td>2026</td></tr><tr><td>REV</td><td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "20fc132f798de2b3",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2026</td><td>2025</td><td>2026</td></tr><tr><td>REV</td><td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><tr><td>2025 (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "72a77d17dba2b1c3",
        "value": -3.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>REV</td><td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><tr><td>2025 ($)</td><td>Q1A</td><td>Q2A</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "73a1bd5b20e95342",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>REV</td><td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><tr><td>2025 ($)</td><td>Q1A</td><td>Q2A</td><td>Q3</td><td>Q4",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "69914635dd999935",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>NA</td><td>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><tr><td>2025 ($)</td><td>Q1A</td><td>Q2A</td><td>Q3</td><td>Q4 FY</td></tr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1d4f3ceb5bb8bd35",
        "value": -0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-10%</td><td>-95%</td><td>-19%</td></tr><tr><td>EPS</td><td>-355%</td><td>-4%</td><td>-2%</td><td>-28%</td></tr><tr><td>2025 ($)</td><td>Q1A</td><td>Q2A</td><td>Q3</td><td>Q4 FY</td></tr><tr><td>EPS",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b019c2a73a58558e",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2 Month View </center> Base Case, \\(\\) 70\\(,\\) +85\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f34129ac9cc07af8",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Case, \\(\\) 70\\(,\\) +85\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 40% PO",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cfa79e0a50dc1e2e",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 40% POS PT of \\(\\) 70\\$ is DCF-",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "51c654c66737bafe",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "74): POS in mild/mod oHCM: 100%, Peak Penetration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 40% POS PT of \\(\\) 70\\$ is DCF- based Upside Sce",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "7c9e42c58096ba07",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "netration rate: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 40% POS PT of \\(\\) 70\\$ is DCF- based Upside Scenario, \\(\\) 142\\(,\\) +275\\%\\$ Aficamte",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2dc0fa55378584a1",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e: 12%; POS in severe oHCM: 100%. POS in nHCM: 30%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 40% POS PT of \\(\\) 70\\$ is DCF- based Upside Scenario, \\(\\) 142\\(,\\) +275\\%\\$ Aficamten (CK- 274): P",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "85a8a841cf1d02f6",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "is DCF- based Upside Scenario, \\(\\) 142\\(,\\) +275\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS i",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "bfbdadc24fa60447",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "io, \\(\\) 142\\(,\\) +275\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS in HFrEF: 20% CK- 586: 80% P",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cfa79e0a50dc1e2e",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$ Aficamten (CK- 274): POS in mild/mod oHCM: 100%, Peak Penetration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS in HFrEF: 20% CK- 586: 80% POS Upside PT of \\(\\) 142\\",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "027a41a9e7c939ab",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "74): POS in mild/mod oHCM: 100%, Peak Penetration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS in HFrEF: 20% CK- 586: 80% POS Upside PT of \\(\\) 142\\$ is DCF- based D",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "9b5d95136b2d820f",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "netration rate: 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS in HFrEF: 20% CK- 586: 80% POS Upside PT of \\(\\) 142\\$ is DCF- based Downside Scenario, \\(\\) 30\\(,\\) - 21\\%\\$",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "05f6bcdf1ea6b391",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": 25%; POS in severe oHCM: 100%. POS in nHCM: 70%; Omecamitv Mecaribl: POS in HFrEF: 20% CK- 586: 80% POS Upside PT of \\(\\) 142\\$ is DCF- based Downside Scenario, \\(\\) 30\\(,\\) - 21\\%\\$ Aficamten (CK",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "dd58aa4cd56aff6f",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "is DCF- based Downside Scenario, \\(\\) 30\\(,\\) - 21\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 75%, Peak Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "901f25ddc35dd2e3",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ario, \\(\\) 30\\(,\\) - 21\\%\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 75%, Peak Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 0% POS",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d37d8435fbc94d2f",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\\$ Aficamten (CK- 274): POS in mild/mod oHCM: 75%, Peak Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 0% POS Downside PT of \\(\\) 30\\$",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "4fb97e2a9cb286be",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "274): POS in mild/mod oHCM: 75%, Peak Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 0% POS Downside PT of \\(\\) 30\\$ is DCF- based ##",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "04131bd57737d142",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Penetration rate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 0% POS Downside PT of \\(\\) 30\\$ is DCF- based ## Sustainability Matters ## Catalysts",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "380d1ae001a2f65c",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ate: 10%; POS in severe oHCM: 75%. POS in nHCM: 0%; Omecamitv Mecaribl: POS in HFrEF: 0% CK- 586: 0% POS Downside PT of \\(\\) 30\\$ is DCF- based ## Sustainability Matters ## Catalysts ## Top Materi",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "32631fc2c81e43ad",
        "value": 13000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "e We Differ 1) At \\(\\sim\\) 88Bn, CYTK trades at a significant discount to what BMY paid for MYOK (\\$13Bn), which has a drug with a similar mechanism of action. 2) Our analysis suggests CYTK's drug, ha",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "fdd010d85f3fa204",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") incidence.** Last year at ESC, we saw an Integrated safety anal ysis (n=283 pts) showing low LVEF<50% incidence (0.7%) during maintenance phase across 206 pt-yrs of drug exposure across REDWOOD, SEQ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e5871f44b2918446",
        "value": 0.006999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Last year at ESC, we saw an Integrated safety anal ysis (n=283 pts) showing low LVEF<50% incidence (0.7%) during maintenance phase across 206 pt-yrs of drug exposure across REDWOOD, SEQUOIA and FOREST",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "831a3a3e9b008688",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "IA uses site-read echoes Q2W (wks 2/4/6) to guide escalation from 5 to 10/15/20mg as long as EF is ≥60%. We'll note that the uptitration criteria for ODYSSEY might not be the same as the Mava/Camzyos ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7d1f0d725bca1739",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Site-read echoes; start 5 mg QD, uptitrate to 10/15/20 mg at Wks 2/4/6. Rules: uptitrate if<br>EF ≥60%; hold 50-&lt;60; downtitrate if &lt;50, temp DC/if &lt;40.</td><td></td><td>Core-lab-read echoes",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2231849be59622ae",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "art 5 mg QD; down-titrate Wks 5 & 9, up-titrate Wks 12/24/36;<br>range 1-15 mg. Interrupt if EF &lt;50%, permanent DC/if &lt;30.</td></tr><tr><td>AF criteria</td><td>AF allowed if rate-controlled. Hig",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6efbe03a1be4914a",
        "value": 0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>NT-proBNP ≥200 (or BNP ≥70; higher if AF) plus ≥1 required criteria criteria (hs-troponin<br>&gt;99% ULN, or E/e' &gt;14, or LAVI &gt;34 mL/m²).</td></tr><tr><td>CPET / oxygenation</td><td>CPET req",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "eda7a81b170a4aed",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "LAVI &gt;34 mL/m²).</td></tr><tr><td>CPET / oxygenation</td><td>CPET required: RER ≥1.0 and pVO&gt;90% predicted. Exclusion if SpO&gt;90% at rest.</td><td></td><td>CPET required: RER ≥1.0 and SpO&gt;9",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a66c633183f079d7",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>CPET / oxygenation</td><td>CPET required: RER ≥1.0 and pVO&gt;90% predicted. Exclusion if SpO&gt;90% at rest.</td><td></td><td>CPET required: RER ≥1.0 and SpO&gt;90% at rest (core-lab read).</td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "05bdf40cea4dd0c5",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "90% predicted. Exclusion if SpO&gt;90% at rest.</td><td></td><td>CPET required: RER ≥1.0 and SpO&gt;90% at rest (core-lab read).</td></tr><tr><td>Inclusion: LVOT &<br>wall thickness</td><td>nHCM: LVOT",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9136da0a9ac3642e",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Inclusion: LVOT &<br>wall thickness</td><td>nHCM: LVOT-G &lt;30 mmHg rest &lt;50 provocation; EF ≥60%; wall thickness ≥15 mm or<br>≥13 mm + FHx/genetics. KCCQ-CSS 30-85.</td><td></td><td>Similar LVO",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3c6c509224d3dbd3",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-lab verified</td></tr><tr><td>Exclusions (key diffs)</td><td>Excludes resistant HTN, O&gt; sat &lt;90%, recent syncope/VT with exertion, inability to exercise,<br>prior mava/aficamten, SRT &lt;6 mo, ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c8b3ab57cf123a10",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "similar between ACACIA and prev. afi trials - looking at the CT gov trial listings,we counted that ~95% of REDWOOD Ph.2 trial centers were rolled forward into ACACIA then expanded broadly (135 sites t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "59711d40deca2fd0",
        "value": -0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "adly (135 sites total with ~50/50 US/ex-US).BMY, in comparison, had slightly lower continuity at ~70-75% of centers from MAVERICK carried forward to ODYSSEY (224 sites total, ~120 ex-US). Trial center",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "099c37c09de9f21f",
        "value": -0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SSEY<br>(nHCM, Ph.3)</td><td>224</td><td>~100+</td><td>~120+</td><td>~22-24<br>(US only)</td><td>~70-75%<br>(US only)</td></tr><tr><td>CYTK</td><td>REDWOOD (o/nHCM,<br>Ph.2)</td><td>22</td><td>19</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "aef412c226a1d675",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3</td><td>ACACIA<br>(nHCM, Ph.3)</td><td>135</td><td>~70-75</td><td>~60-65</td><td>~21</td><td>~95% (US<br>+ ex-US)</td></tr></table> Source: JEF Analysis, CT.gov In the full ODYSSEY data, we'll b",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "300fd044f0a77137",
        "value": -0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e'll be paying attention to % of pts achieving 1Smg dose - our est. suggests this could be up to ~27-34% of pts: Going into ESC, one thing we'll be paying attention to is how many pts got onto the max",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fc732c52329bb16f",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(vLVOT and LVEF) titration to estimate dose distribution in oHCM. At week 48 (ODYSSEY's endpoint), ~19% of pts were estimated to be at the max 15mg dose.<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5624483a72976bd4",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\\(\\sim 1.67 \\times [= 90\\% /54\\% ]\\) Applying our derived multiplier (1.67x) to our starting value (19%), we get a theoretical \\(\\sim 32\\%\\) estimate for pts reaching 15mg. If the relative increase we",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e22bfbab332a21ea",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e' <table><tr><td>Description</td><td>% of pts</td></tr><tr><td>Base 15 mg % from ER Model</td><td>19%</td></tr><tr><td>% with LVEF ≥55% (eligible based on EF)</td><td>90%</td></tr><tr><td>% with both",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "00c1c8dfbf7389fa",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>% of pts</td></tr><tr><td>Base 15 mg % from ER Model</td><td>19%</td></tr><tr><td>% with LVEF ≥55% (eligible based on EF)</td><td>90%</td></tr><tr><td>% with both LVEF ≥55% and LVOT ≥30 mmHg</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "557f79839f18771e",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "15 mg % from ER Model</td><td>19%</td></tr><tr><td>% with LVEF ≥55% (eligible based on EF)</td><td>90%</td></tr><tr><td>% with both LVEF ≥55% and LVOT ≥30 mmHg</td><td>54%</td></tr><tr><td>Relative in",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "95aef6b3c00dfb7d",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>% with LVEF ≥55% (eligible based on EF)</td><td>90%</td></tr><tr><td>% with both LVEF ≥55% and LVOT ≥30 mmHg</td><td>54%</td></tr><tr><td>Relative increase in eligible patients w/o LVOT g",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "48812380716a9890",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(eligible based on EF)</td><td>90%</td></tr><tr><td>% with both LVEF ≥55% and LVOT ≥30 mmHg</td><td>54%</td></tr><tr><td>Relative increase in eligible patients w/o LVOT gate</td><td>1.67</td></tr><tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "adb0d1f1655197d2",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ble patients w/o LVOT gate</td><td>1.67</td></tr><tr><td>Theoretical max 15 mg % in ODYSSEY</td><td>32%</td></tr></table> ![Figure 3-0](images/3_0.jpg) <center>REDWOOD cohort 4 Figure 3: 35 patients (",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c6c13f48518d4cf9",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr></table> ![Figure 3-0](images/3_0.jpg) <center>REDWOOD cohort 4 Figure 3: 35 patients (8%) achieved daily aftertome dose of pts. 6 patients (15%) achieved 10 mg. 1 patient on 10 mg. 1 patie",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fe848adce3e7f0d8",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nter>REDWOOD cohort 4 Figure 3: 35 patients (8%) achieved daily aftertome dose of pts. 6 patients (15%) achieved 10 mg. 1 patient on 10 mg. 1 patient on 10 mg. 1 patient on 10 mg </center> Source: JEF",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "15c169e7f3e5054b",
        "value": 9.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>2039</td><td>2040</td></tr><tr><td>Jefferies</td><td>Total Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ed94aa93cd3789b3",
        "value": 5.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "2039</td><td>2040</td></tr><tr><td>Jefferies</td><td>Total Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a78c76ce2ebd362e",
        "value": 356.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0</td></tr><tr><td>Jefferies</td><td>Total Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "5bebbb2292bb5bdb",
        "value": 3.35,
        "unit": "$",
        "metric_type": "currency",
        "context": "<tr><td>Jefferies</td><td>Total Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "51ec828e6ac42f4d",
        "value": 539.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "s</td><td>Total Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d51e60a0e570e6b0",
        "value": 2.13,
        "unit": "$",
        "metric_type": "currency",
        "context": "otal Revenue<br/>Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b389b60bf42fd637",
        "value": 842.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">Diluted EPS</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "23e2e0dfcc47d982",
        "value": 1.17,
        "unit": "$",
        "metric_type": "currency",
        "context": "S</td><td>$ 9<br/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8e8227b5121cb113",
        "value": 1260.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/>($ 5.55)</td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c229bad0249fe5b7",
        "value": 0.97,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 356<br/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "875004ac3ca8e59d",
        "value": 1741.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/>($ 3.35)</td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "037067319873b7ef",
        "value": 2.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 539<br/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2a000f59010f5152",
        "value": 2145.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/>($ 2.13)</td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "69005b9389f5cd38",
        "value": 4.69,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 842<br/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fe7f4eaecb6e03a2",
        "value": 2331.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/>($ 1.17)</td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "74a5b00f65dbd8e0",
        "value": 5.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 1,260<br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e59ef7b146accca2",
        "value": 2461.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 0.97</td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "70f0d18e9f341984",
        "value": 5.83,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 1,741<br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "5ded59e2476bcbf1",
        "value": 2591.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 2.79</td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0445a02cab4bd1a8",
        "value": 6.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,145<br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fc8f79bcb914cdbf",
        "value": 2693.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 4.69</td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2a1d4c08166d0f41",
        "value": 6.77,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,331<br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a64955bda9e23d94",
        "value": 2765.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 5.38</td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9a1863b031d12a76",
        "value": 7.02,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,461<br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ffde3859310089e1",
        "value": 2838.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 5.83</td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b38b29bab2c4a307",
        "value": 7.26,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,591<br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0ccc2da757911d79",
        "value": 2912.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 6.38</td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3ceb89f1c993034d",
        "value": 7.53,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,693<br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><tr><td>GAAP P",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "069d6bdc74856403",
        "value": 2986.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 6.77</td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><tr><td>GAAP PNL</td><td></td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2ca4443c157c88c9",
        "value": 7.78,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,765<br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><tr><td>GAAP PNL</td><td></td><td></td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "55904f87fdf50e11",
        "value": 2671.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "br/>$ 7.02</td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><tr><td>GAAP PNL</td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3979b346291d6a90",
        "value": 7.15,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 2,838<br/>$ 7.26</td><td>$ 2,912<br/>$ 7.53</td><td>$ 2,986<br/>$ 7.78</td><td>$ 2,671<br/>$ 7.15</td></tr></table> <table><tr><td>GAAP PNL</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b9b2cef7d07e2dc9",
        "value": 0.97,
        "unit": "$",
        "metric_type": "currency",
        "context": "tr><td>GAAP EPS - basic</td><td>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d379406893c3a22b",
        "value": 2.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "- basic</td><td>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "afe8b34e9e5a4394",
        "value": 4.69,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bceb490ee0be428a",
        "value": 5.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3158616f539f16a3",
        "value": 5.83,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f861c47cc59ba6aa",
        "value": 6.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c24e8b72734f0eef",
        "value": 6.77,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>G",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "51729e0d0aa3247c",
        "value": 7.02,
        "unit": "$",
        "metric_type": "currency",
        "context": "7</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>GAAP EPS - dilut",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "80188c80374bfe41",
        "value": 7.26,
        "unit": "$",
        "metric_type": "currency",
        "context": "9</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>GAAP EPS - diluted</td><td>$ (5",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8b0a34ec919b0452",
        "value": 7.53,
        "unit": "$",
        "metric_type": "currency",
        "context": "9</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>GAAP EPS - diluted</td><td>$ (5.55)</td><td>$ ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bb9931cc02117210",
        "value": 7.78,
        "unit": "$",
        "metric_type": "currency",
        "context": "8</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>GAAP EPS - diluted</td><td>$ (5.55)</td><td>$ (3.35)</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "53b9fcc28fe43291",
        "value": 7.15,
        "unit": "$",
        "metric_type": "currency",
        "context": "3</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td></tr><tr><td>GAAP EPS - diluted</td><td>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9c21e9f281b8e4f1",
        "value": 0.97,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>GAAP EPS - diluted</td><td>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e7166e3a96668b52",
        "value": 2.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "diluted</td><td>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "afe8b34e9e5a4394",
        "value": 4.69,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$ (5.55)</td><td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bceb490ee0be428a",
        "value": 5.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>$ (3.35)</td><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3158616f539f16a3",
        "value": 5.83,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$ (2.13)</td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f861c47cc59ba6aa",
        "value": 6.38,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$ (1.17)</td><td>$ 0.97</td><td>$ 2.79</td><td>$ 4.69</td><td>$ 5.38</td><td>$ 5.83</td><td>$ 6.38</td><td>$ 6.77</td><td>$ 7.02</td><td>$ 7.26</td><td>$ 7.53</td><td>$ 7.78</td><td>$ 7.15</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d29fb6baf1ddc633",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c4febd64774be29c",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "eaf4574a1c71ad70",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1c451ec6cd97507b",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "8d3f7daf14056343",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2eaf409521330b4f",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "47807f25aee77086",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "98dfd242511de186",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d9b21d74cc9f02a4",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 6,
      "tables_count": 0,
      "numerical_data_count": 124,
      "passages_count": 109,
      "entities_count": 20
    }
  }
}